MicroRNA-30c Mimic Mitigates Hypercholesterolemia and Atherosclerosis in Mice by Irani, Sara et al.
MicroRNA-30c Mimic Mitigates Hypercholesterolemia
and Atherosclerosis in Mice*□S
Received for publication,March 21, 2016, and in revised form, May 28, 2016 Published, JBC Papers in Press, June 30, 2016, DOI 10.1074/jbc.M116.728451
Sara Irani‡§, Xiaoyue Pan§, Bailey C. E. Peck¶, Jahangir Iqbal§, Praveen Sethupathy¶, andM.MahmoodHussain§**‡‡1
From the ‡Molecular and Cell Biology Program, School of Graduate Studies and §Departments of Cell Biology and Pediatrics, State
University of New York (SUNY) Downstate Medical Center, Brooklyn, New York 11203, ¶Curriculum in Genetics andMolecular
Biology, Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, **Veterans Affairs New York
Harbor Healthcare System, Brooklyn, New York 11422, and ‡‡Winthrop University Hospital, Mineola, New York 11501
High plasma cholesterol levels are a major risk factor for ath-
erosclerosis. Plasma cholesterol can be reduced by inhibiting
lipoprotein production; however, this is associated with steato-
sis. Previously we showed that lentivirally mediated hepatic
expression of microRNA-30c (miR-30c) reduced hyperlipi-
demia and atherosclerosis in mice without causing hepatoste-
atosis. Because viral therapy would be formidable, we examined
whether a miR-30c mimic can be used to mitigate hyperlipi-
demia and atherosclerosis without inducing steatosis. Delivery
of a miR-30c mimic to the liver diminished diet-induced hyper-
cholesterolemia in C57BL/6J mice. Reductions in plasma cho-
lesterol levels were significantly correlated with increases in
hepatic miR-30c levels. Long term dose escalation studies
showed that miR-30c mimic caused sustained reductions in
plasma cholesterol with no obvious side effects. Furthermore,
miR-30cmimic significantly reduced hypercholesterolemia and
atherosclerosis in Apoe/ mice. Mechanistic studies showed
thatmiR-30cmimic had no effect on LDL clearance but reduced
lipoprotein production by down-regulatingmicrosomal triglyc-
eride transfer protein expression.MiR-30c hadno effect on fatty
acid oxidation but reduced lipid synthesis. Additionally, whole
transcriptome analysis revealed that miR-30c mimic signifi-
cantly down-regulated hepatic lipid synthesis pathways. There-
fore, miR-30c lowers plasma cholesterol and mitigates athero-
sclerosis by reducing microsomal triglyceride transfer protein
expression and lipoprotein production and avoids steatosis by
diminishing lipid syntheses. It mitigates atherosclerosis most
likely by reducing lipoprotein production and plasma choles-
terol. These findings establish that increasing hepatic miR-30c
levels is a viable treatment option for reducing hypercholester-
olemia and atherosclerosis.
Atherosclerosis, hardening of the arteries secondary to lipid
deposition, is the major cause of morbidity andmortality in the
United States (1–3). High plasma cholesterol levels are a major
risk factor for cardiovascular diseases, and their reduction is a
national goal (2, 4). Currently, statins are the standard of care.
They lower plasma cholesterol by reducing cholesterol synthe-
sis and enhancing the rate of removal of lipoproteins from the
plasma. Statins lower plasma cholesterol by 20–30% and car-
diovascular disease mortality by 30–40% (5–8). Recently, pro-
protein convertase subtilisin/kexin type 9 (PCSK9)2 inhibitors
have emerged as potential new drugs for the treatment of
hyperlipidemia (9). PCSK9 binds to LDL receptor and targets it
for lysosomal degradation. Thus, inhibition of PCSK9 leads to
increased LDL receptor expression, increased clearance of lipo-
proteins, and decreased plasma LDL cholesterol levels (10–12).
Because both statins and PCSK9 antibodies reduce plasma cho-
lesterol by modulating LDL receptor expression, they are inef-
fective in homozygous familial hypercholesterolemia subjects
with2% of the LDL receptor activity (11, 13, 14). In addition,
a significant percentage of the general population experiences
significant side effects with statins and PCSK9 inhibitors
(13–15).
A complementary approach to lower plasma cholesterol is to
inhibit lipoprotein synthesis and secretion to reduce their entry
into the circulation. Lipoprotein production requires a struc-
tural protein apolipoprotein B (apoB) and a chaperone, micro-
somal triglyceride transfer protein (MTP) (16, 17). Because
apoB does not have anymeasurable activity, its levels have been
lowered using an antisense oligonucleotide, mipomersen (8,
18). This drug has been approved for the treatment of familial
hypercholesterolemia subjects who have high plasma choles-
terol and do not respond to statins (19). However, compared
with apoB,MTPhas been amore favored target to lower plasma
lipids because its lipid transfer activity can bemeasured in vitro
and it is amenable to high throughput screening for drug devel-
opment. Virtually all of the major pharmaceutical companies
have, at some point, developed drugs that potently inhibitMTP
activity and lower plasma lipids. However, these drugs increase
plasma transaminases, markers of liver injury, fatty liver dis-
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ease, and hepatosteatosis (20–23). One MTP inhibitor, lomi-
tapide, has been approved for the treatment of familial hyper-
cholesterolemia (8, 24, 25). Both lomitapide and mipomersen
carry warning labels for hepatic steatosis. Hence, there is a need
for new drugs that can lower plasma lipids while avoiding
steatosis.
Discovery of endogenous microRNAs (miRs) provides a new
way of treating dyslipidemia and associated cardiovascular dis-
ease (26, 27). MiRs are endogenous gene products of 22
nucleotides. They interact predominantly with the 3-untrans-
lated regions (3-UTRs) of target mRNAs and reduce protein
synthesis by augmentingmRNA degradation or by diminishing
translation (28, 29);mRNAdegradation appears to be themajor
mechanism in mammalian systems (30). Different miRs and
anti-miRs are in clinical trials for the treatment of various
pathologies (31–33) and are expected to be the drugs of the
future.
Our previous work showed that lentivirally mediated over-
expression of miR-30c decreases hepatic MTP expression and
activity, lowers plasma cholesterol, and reduces hepatic lipo-
protein production without altering hepatic lipids and plasma
transaminases in Western diet-fed C57BL/6J (WT) mice (34).
Also, lentivirally mediated hepatic overexpression of miR-30c
reduced plasma cholesterol and mitigated atherosclerotic
plaques in Western diet-fed Apoe/ mice (34). Because viral
delivery to humans for therapeutic use may pose several chal-
lenges, we hypothesize that miR-30c analogues can be used to
treat hypercholesterolemia and atherosclerosis in statin-intol-
erant and familial hypercholesterolemia patients. To begin test-
ing this hypothesis, we performed preclinical studies using a
stabilized analogue ofmiR-30c (“mimic”) to evaluate its efficacy
andmolecular mechanisms in lowering plasma cholesterol and
atherosclerosis in mice.
Results
Custom SynthesizedMiR-30cMimic ReducesMTP Expression
and ApoB Secretion in HumanHepatoma Cells
To test the biological potency of the custom synthesized
mimic, we transfected human hepatoma Huh-7 cells with the
miR-30c mimic or a scrambled control miR (Scr) (Fig. 1).
Increasing concentrations of miR-30c mimic significantly
reduced MTP activity and apoB secretion compared with Scr
(Fig. 1, a and b). The effect of miR-30c reached a maximum at
50 nM. Thismostly likely represents saturation of RISCmachin-
ery with miR-30cRISC complexes. Furthermore, time course
studies revealed that maximum reductions inMTP activity and
apoB secretion occurred 48 h after transfections, and the effect
of miR-30c was lost after 96 h (Fig. 1, c and d). These results are
in concert with our previous studies (34), suggesting that the
custom synthesized miR-30c mimic is biologically active in
reducing MTP activity and apoB secretion in hepatoma cells.
MiR-30cMimicMitigates Progression of Diet-induced
Hypercholesterolemia inMice
To determine whether the mimic can prevent progression of
diet-induced hyperlipidemia, miR-30c mimic and Scr were
complexed with lipid emulsions and injected into male WT
mice placed on a Western diet (Fig. 2). Plasma cholesterol
increased in both miR-30c mimic- and Scr-injected groups.
However, increases in plasma cholesterol levels were signifi-
cantly lower (21 to 26%) in the miR-30c mimic group com-
pared with the Scr group (Fig. 2a). Fasting plasma triglyceride,
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), glucose (Fig. 2, b–e), and creatine kinase (CK) levels
were not different between the two groups. Moreover, we did
not see changes in food intake between both groups. Analyses
of different tissues showed that miR-30c levels increased by 6-
and 15-fold in the livers and spleens, respectively, of mice
receiving the mimic; there were no significant differences in
miR-30c levels in the kidney, heart, and jejunum (Fig. 2f). In a
separate experiment, we observed that miR-30c was not deliv-
ered to adipose tissue (data not shown). In contrast tomiR-30c,
the hepatic levels of another miR-30 family member, miR-30b,
were unaffected (Fig. 2g). Hepatic MTP activity was signifi-
cantly reduced (42%) in the miR-30c mimic group (Fig. 2h)
with no effect on hepatic triglyceride and cholesterol levels (Fig.
2, i and j). These studies suggest that the delivery of miR-30c
mimic to the liver curtailed progression of diet-induced hyper-
cholesterolemia with no effect on hepatic lipids and plasma
enzymes.
Regression of Diet-induced Hypercholesterolemia byMiR-30c
Mimic
Next, we asked whether miR-30c mimic can reduce plasma
cholesterol in hyperlipidemic mice. Male WT mice were fed a
Western diet for 4 weeks to induce hyperlipidemia and divided
into three groups. One group received PBS, and the other two
groups received different doses of eithermiR-30cmimic or Scr.
There were no significant differences between PBS and Scr
FIGURE 1. Effect of different concentrations of miR-30cmimic on cellular
MTP activity and apoB secretion in Huh-7 cells. a and b, MTP activity (per-
cent triglyceride transfer mg1 h1) in cells (a) and apoB concentrations (ng
mg1 of cell protein; determined by ELISA) (b) in culturemedia of Huh-7 cells
transfectedwith increasing concentrationsof Scr ormiR-30cmimicmeasured
48 h after transfection. MTP activity and apoB secretion were normalized to
non-transfectedcells. Therewasno significantdifferencebetweennon-trans-
fected and Scr-transfected cells (not shown). c and d, time course of changes
inMTP activity (c) and apoB concentration (d) in cells andmedia, respectively,
transfected with 100 nM Scr or miR-30c mimic. MTP activity and apoB secre-
tion at time 0 were set to 100%. The data are representative of two indepen-
dent experiments. All data are shown as the mean S.D. *, p 0.05; **, p
0.01; ***, p 0.001. Standard deviations are presented as error bars.
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groups for the various metabolic parameters studied (Fig. 3),
indicating that Scr does not affect these parameters. MiR-30c
mimic did not affect plasma cholesterol at a single dose of 2.5
mg/kg/week compared with Scr and PBS groups. However, at a
5 mg/kg/week dose, significant sustained reductions in plasma
cholesterol levels were seen in the mimic group compared with
the Scr or PBS group, reaching amaximal reduction of 38% (Fig.
3a). Plasma triglyceride, AST, and ALT in the mimic group
were not significantly different from those in the Scr and PBS
groups (not shown). These studies indicate thatmiR-30cmimic
reduces plasma cholesterol inWestern diet-fed hyperlipidemic
mice without affecting plasma triglyceride and transaminases.
Tissue analysis revealed that miR-30c levels increased by 13-
and 20-fold in the livers and spleens, respectively, but remained
unchanged in kidney, heart, and jejunum of mice injected with
the mimic (Fig. 3b). Contrary to miR-30c, hepatic miR-30b was
not increased in themimic-injected group compared with con-
trol groups (Fig. 3c). Expression levels of miR-30c putative tar-
get genes (Mttp, Lpgat1, Qki, and Elovl5) were significantly
reduced in the mimic group compared with the PBS and Scr
groups, whereas no significant changes were observed for non-
target genes (ApoA1 and Gapdh) (Fig. 3d). Additionally, MTP
activity was significantly lower in the mimic group compared
with control groups (Fig. 3e). Moreover, there were no signifi-
cant differences in hepatic cholesterol and triglyceride levels
(not shown). These studies show that miR-30c reduced hepatic
MTP activity without causing steatosis.
The studies in Figs. 2 and 3 showed that miR-30c injections
reduced plasma cholesterol and increased hepatic miR-30c lev-
els. To determine whether these two observations were related,
we carried out a Spearman correlation analysis. There was a
significant positive correlation between increases in hepatic
miR-30c levels and percent reductions in plasma cholesterol
levels. The slope of the curve was2, predicting that a2-fold
increase in hepatic miR-30c might reduce plasma cholesterol
by 50%. Thus, there is a significant positive correlation between
hepatic miR-30c accretions and plasma cholesterol reduction.
Time Course and Long TermDose Escalation Studies Revealed
Sustained Reductions in Plasma Cholesterol
Next, we studied the time course and long term effects of
escalating doses of miR-30c mimic in female WT mice that
were fed aWestern diet for 4 weeks (Fig. 4). In previous studies,
we used male mice. Here, we used females to demonstrate uni-
versality of miR-30c effects. After a single injection of 5 mg/kg/
week miR-30c mimic, significant reductions in plasma choles-
terol were evident on day 2, and the highest reduction of 21%
was on day 6 (Fig. 4a). After day 10, plasma cholesterol reverted
to normal levels as in the PBS group. Next, we asked whether
successive injections would elicit a similar response. Two sub-
sequent injections of 5 mg/kg/week significantly decreased
plasma cholesterol until day 6; plasma cholesterol returned to
normal on day 10 (Fig. 4a). We then increased the dose to 7.5
mg/kg/week and observed a similar response; plasma choles-
terol was reduced for 6 days and subsequently rebounded to
normal levels (Fig. 4a). Increasing the dose to 10mg/kg/week by
injecting 5 mg/kg on 2 consecutive days reduced plasma cho-
lesterol by 39%. Two subsequent 10 mg/kg/week injections
reduced plasma cholesterol by 36–40% when compared with
the PBS group. There were no significant differences in plasma
triglycerides in these groups throughout the study. Mice were
then subjected to euthanasia 6 days after the last injection.
FPLC analysis of pooled plasma revealed reduced cholesterol
levels in the VLDL/LDL fraction (Fig. 4b, left) with no effect
on triglyceride (not shown). Quantification of areas under
the curve revealed a 30% reduction of cholesterol in the
VLDL/LDL fraction (Fig. 4b, right). The plasma of miR-30c
mimic-injected mice had significantly lower apoB100 and
apoB48, but apoA-I levels were not different (Fig. 4c). These
long term studies involving multiple injections had no effect
FIGURE 2. MiR-30c mimic dampens progression of diet-induced hyper-
cholesterolemia. Male C57BL/6J mice (8 weeks old) were injected with 7.5
mg/kg/week miR-30c mimic (n 5) or Scr miR (n 4) complexed with lipid
emulsions and startedonaWesterndiet. Fastingplasmawas collectedonday
6 after each injection to measure cholesterol (a), triglyceride (b), ALT (c), AST
(d), and glucose (e). 48 h after the last injection, mice were euthanatized.
Different tissues were also collected to measure miR-30c levels (f). Hepatic
tissueswere used tomeasuremiR-30b (g), MTP activity (h), cholesterol (i), and
triglyceride (j). *, p  0.05; **, p  0.01; ***, p  0.001 as determined by
Student’s t test. Standard deviations are presented as error bars.
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on plasma ALT, AST, and CK activities and phospholipids
and food intake. Hepatic analysis of miR-30c levels revealed
an 4-fold increase in miR-30c levels. Furthermore, MTP
mRNA was significantly reduced in the miR-30c mimic-in-
jected group (Fig. 4d). Additionally, there was a 50% reduc-
tion in hepatic MTP, but not GAPDH, protein (Fig. 4e). In
contrast, hepatic cholesterol, triglyceride, and phospholip-
ids were not different between the treatment groups (not
shown). These studies indicated that a single injection of
miR-30c lowers plasma cholesterol in VLDL/LDL for about a
week in a dose-dependent manner. Furthermore, multiple
injections consistently reproduce these effects with no obvi-
ous long term adverse effects.
Mechanisms Explaining the Lowering of Plasma Cholesterol
MiR-30c Mimic Does Not Affect LDL Clearance—To under-
stand physiological mechanisms for reductions in plasma cho-
lesterol, we first aimed at studying whether miR-30c mimic
increases LDL clearance and therefore reduces plasma choles-
terol. MaleWTmice were fed aWestern diet and injected with
either PBS or miR-30c mimic for 2 weeks. MiR-30c mimic sig-
nificantly reduced plasma cholesterol by33% without affect-
ing plasma triglyceride. LDL clearance studies showed that
miR-30c mimic had no significant effect on apoB and apoA-I
clearance (not shown), indicating that miR-30cmimic does not
increase the rate of LDL clearance.
MiR-30cMimic ReducesHepatic, butNot Intestinal, Lipopro-
tein Production—To explain how miR-30c mimic reduces
plasma cholesterol, we performed hepatic lipoprotein produc-
tion studies in separate sets of animals (Fig. 5). MiR-30c mimic
maximally reduced plasma cholesterol concentrations by 39%
(not shown) as a result of changes in non-high density lipopro-
teins (Fig. 5a). However, it did not significantly affect triglycer-
ides in the whole plasma or within different lipoprotein frac-
tions (Fig. 5b). After the injection of poloxamer 407 to inhibit
lipoprotein lipases (35), themiR-30cmimic group accumulated
FIGURE 3.MiR-30cmimic causes regression of diet-induced hypercholesterolemia.Male C57BL/6Jmice (8 weeks old) were fed aWestern diet for 4 weeks
and then injected weekly with PBS or increasing doses of Scr or miR-30c mimic for 6 weeks. Animals remained onWestern diet during the entire experiment.
a, plasmawas collected fromovernight fastedmice 6 days after every injection tomeasure cholesterol. b, 48 h after the last injection, tissues were collected to
measure miR-30c levels. c–e, hepatic tissues were used to measure miR-30b levels (c), different indicated mRNAs (d), and MTP activity (e). The data are
representative of two independent experiments. Statistical significance is represented as follows: #, p 0.05; ##, p 0.01; ###, p 0.001 as determined by
one-way analysis of variance (#) and Student t test (p) compared with the PBS group. Standard deviations are presented as error bars.
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lower amounts of plasma triglycerides (Fig. 5c) due to signifi-
cantly reduced triglyceride production rates (207 mgdl1h1)
compared with controls (334 mgdl1h1). Furthermore, the
amounts of newly synthesized and secreted apoB100 and
apoB48, but not apoA-I, were lower in the plasma of the miR-
30c mimic group (Fig. 5d). These studies indicate that miR-30c
mimic lowers hepatic production of triglyceride-rich apoB-
containing lipoproteins.
Besides the liver, the intestine is another major organ
involved in lipoprotein synthesis and secretion. Therefore, we
asked whether miR-30c mimic also influences intestinal lipo-
protein production. Therewere no significant differences in the
absorption of lipids between the PBS and miR-30c mimic
groups (Fig. 5, e and f). This is consistent with no accretions of
miR-30c in the jejunum (Fig. 3e). Thus, intravenous injection of
miR-30c mimic has no effect on intestinal lipid absorption as it
is not delivered to the jejunum.
MiR-30cMimic Does Not Lower Plasma Cholesterol in Liver-
specific MTP-deficient Mice—To further test the hypothesis
that miR-30c mimic reduces hepatic lipoprotein production pri-
marily through suppression of MTP activity, we examined the
effect of the mimic in Western diet-fed, liver-specific MTP-defi-
cient (Albumin-Cre:Mttpflox/flox, L-Mttp/) mice that do not
secrete lipoproteins from the liver (36). MiR-30c mimic had no
effect on cholesterol and triglyceride in total plasma and different
lipoprotein fractions (Fig. 6a and data not shown). Moreover,
therewere no significant differences in plasmaALT,AST, andCK
activities between the PBS andmimic groups. Hepatic tissue anal-
ysis indicated that miR-30c levels were significantly increased
(5-fold) in the mimic group, and predicted miR-30c targets were
significantly lower in the mimic group compared with the PBS
group, whereas those of non-target geneswere not (Fig. 6b).More
interestingly, asopposedtoWTmice,miR-30cmimicsignificantly
reducedhepatic cholesterol and triglyceride inL-Mttp/ (Fig. 6, c
FIGURE4.Timecourseand long termeffectsof escalatingdosesofmiR-30cmimic. FemaleC57BL/6Jmice (8weeksold)were fed aWesterndiet for 4weeks
to induce hyperlipidemia and then injected with either PBS (control) or miR-30cmimic at different times as shown. Mice were fasted overnight before plasma
was collected on days 2, 6, 10, and 14 after each injection. a, plasma was used to measure cholesterol. b, at the end, mice were euthanized, and plasma was
collected 6 days after the last injection and subjected to FPLC to measure cholesterol (left panel) and the corresponding area under the curve in the PBS and
mimic groups (right panel) in the VLDL fraction. c, apoB and apoA-I were detected byWestern blotting in individual mouse plasma sample. d and e, livers were
collected to measure MTP mRNA (d) and protein (e). *, p 0.05; **, p 0.01; ***, p 0.001. Standard deviations are presented as error bars.
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and d). These studies suggest that the effect of the mimic on
plasmacholesterol ismainly through suppressionofMTP.And, in
the absence of MTP, miR-30c does not lower plasma cholesterol
but does lower hepatic lipids.
Mechanisms Explaining the Absence of Hepatic Steatosis
MiR-30c Mimic Reduces Hepatic Lipid Synthesis Indepen-
dently of MTP Function—To learn about the regulation of
hepatic lipid metabolism by miR-30c and to understand how
miR-30c mimic reduces hepatic lipoprotein production with-
out increasing hepatic lipid concentrations, we performed
hepatic fatty acid oxidation; de novo lipogenesis; and triglycer-
ide, cholesterol, and phospholipid biosyntheses using fresh
liver slices obtained from WT and L-Mttp/ mice in Figs. 2
and 6, respectively (Fig. 7). MiR-30c mimic did not affect fatty
acid oxidation (Fig. 7a) but significantly reduced fatty acid, trig-
lyceride, and cholesterol syntheses comparedwith PBS controls
in WT mice (Fig. 7, b–d). Similarly, miR-30c treatment in
L-Mttp/mice did not affect fatty acid oxidation (Fig. 7e) but
significantly reduced de novo lipogenesis as well as triglyceride
and cholesterol syntheses (Fig. 7, f–h). These studies suggest
that miR-30c mimic reduces hepatic lipid synthesis indepen-
dently of MTP, and this might avoid hepatic steatosis usually
associated with reductions in lipoprotein production.
MiR-30c Mimic Prominently Suppresses Lipid Metabolic
Pathways—To understand global effects of miR-30c on gene
expression,weperformedwhole transcriptomeanalysis on the liv-
ers obtained from mice in Fig. 3. High throughput RNA-seq
yieldedanaverageof77million readsper sampleofwhich79%
weremapped to themouse transcriptome (supplemental Table S1).
MiR-30c mimic down-regulated 576 genes compared with
both PBS and Scr (Fig. 8a). Surprisingly, a higher number of
genes (n  1342) were up-regulated by miR-30c mimic. Using
miRHub, we observed that the down-regulated genes were sig-
nificantly enriched for predicted target sites ofmiR-30c, but the
up-regulated geneswere not (Fig. 8b). Thus, themiR-30cmimic
down-regulates a small set of genes expressed in the liver
(4%), many of which are likely direct miR-30c targets, and
up-regulates a larger set of genes (10%) via unknown indirect
mechanisms.
FIGURE 5.MiR-30c mimic reduces triglyceride-rich apoB-containing lipoprotein production.Male C57BL/6J mice (n 4 per group) were fed a Western
diet for 4weeks and thenweekly injectedwith PBS ormiR-30cmimic (5.0mg/kg) for 2weeks. a and b, after overnight fasting, plasmawas collected tomeasure
cholesterol (a) and triglycerides (b) in different lipoprotein fractions after precipitation. c and d, 2 days after the last miR-30c or PBS injection, mice were fasted
for 18 h and injected with poloxamer 407 and 35S Pro-Mix to study hepatic lipoprotein production. c, a time course of changes in plasma triglyceride was
measured. d, immunoprecipitation of apoB and apoA-I in plasma obtained at 2 h. Values are shown relative to PBS. *, p 0.05; **, p 0.01; ***, p 0.001 as
determined by Student’s t test. Standard deviations are presented as error bars. e and f, in a different set of animals, 2 days after the last injection ofmiR-30c or
PBS, mice were injected with poloxamer 407 and gavaged with olive oil, cholesterol, [3H]cholesterol, and [14C]triolein. Time courses of cholesterol (c) and
triglyceride (d) intestinal absorption were measured.
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Pathway enrichment analysis revealed that genes down-reg-
ulated by miR-30c mimic are over-represented in lipid meta-
bolic processes (Fig. 8, c and d). Indeed, miR-30c mimic signif-
icantly reduced the expression of numerous genes encoding
lipid synthesis enzymes such as Lpin1, Lpin2, Gpam, Agpat6,
Fads3, Fads2, Scd1, Elovl5, and Elovl6, which might play an
important role in diet-induced steatosis and obesity. These
findings are consistent with reduced hepatic fatty acid and trig-
lyceride syntheses observed in Fig. 7. Surprisingly, we observed
significant increases in Srebp-2 and Pcsk9 levels. However,
these increases were not accompanied with increases in choles-
terol synthesis and LDL clearance.
Regression of Atherosclerosis byMiR-30cMimic
The studies described above show that miR-30c reduces
plasma cholesterol in hyperlipidemic mice by reducing hepatic
lipoprotein production. To determine whether miR-30c mimic
can cause regression of atherosclerosis,Apoe/mice were fed
aWestern diet for 1month, divided in two groups, and injected
with either PBS or miR-30c mimic at a dose of 7.5 mg/kg/week
for 4 weeks (Fig. 9). MiR-30c mimic significantly reduced
plasma cholesterol up to 38% (Fig. 9a) without affecting plasma
triglyceride, ALT, AST, and CK levels. Tissue analysis revealed
significant increases in plasma, liver, and spleen miR-30c levels
with no change in kidney, heart, and jejunum (Fig. 9b). Hepatic
levels of putative miR-30c target genes (Mttp, Lpgat1,QKI, and
Elovl5) were significantly reduced, whereas non-target genes
(ApoA1 and Gapdh) were not. MTP activity was significantly
reduced in themimic group (Fig. 9c). There were no differences
in hepatic cholesterol and triglyceride levels. Furthermore, we
visualized plaques at the aortic arches and detected fewer
plaques in the mimic group compared with the PBS group (Fig.
9d). Oil Red O staining of aortas revealed30% less lipid stain-
ing in the miR-30c group (Fig. 9, e and f). These studies showed
that the miR-30c mimic survives plasma excursions, reaches
the liver, lowers plasma cholesterol, and causes regression of
atherosclerosis without causing hepatosteatosis or increasing
plasma transaminases.
Discussion
Previously, we showed that lentivirally mediated hepatic
expression of miR-30c lowers plasma cholesterol and athero-
sclerosis in mice (34). Because lentiviral delivery of miR-30c
would be formidable for therapeutic purposes, we evaluated the
hypothesis that a synthetic miR-30c mimic might be a suitable
treatment modality in both male and female mice. Here, we
show for the first time that weekly injections of a miR-30c
mimic elevate hepatic miR-30c levels with no significant effect
on miR-30b expression. This treatment results in sustained
reductions in plasma cholesterol levels in Western diet-fed
male and female WT and Apoe/mice, indicating equal effi-
ciency in both genders. The effect of miR-30c was dose-depen-
dent, and the maximum effect on plasma cholesterol was
observed 6 days after each injection. Furthermore, we show that
weekly injections of amiR-30cmimic also reduce atherosclero-
sis in Western diet-fed Apoe/ mice. These reductions in
FIGURE 6. MiR-30c mimic does not reduce plasma cholesterol in liver-
specific MTP deficient mice. Eight-week-old male L-Mttp/ mice were
injected retro-orbitally with either PBS or miR-30c mimic (5. 0 mg/kg) and
startedonaWesterndiet for 4weeks.Micewere fastedovernight, andplasma
was collected 4 days after each injection. a, cholesterol wasmeasured in total
plasma. b–d, livers were collected 48 h after the last injection to measure
different mRNAs (b), cholesterol (c), and triglyceride (d). *, p  0.05; **, p 
0.01 as determined by Student’s t test. Standard deviations are presented as
error bars.
FIGURE 7.MiR-30c mimic reduces hepatic lipid synthesis independently
of MTP function. a–d, WT liver slices from Fig. 2 were used to measure fatty
acid (FA) oxidation (a) as well as fatty acid (b), triglyceride (c), and cholesterol
(d) syntheses. *, p 0.05; **, p 0.01 as determined by Student’s t test. e–h,
liver slices from L-Mttp/mice from Fig. 6 were used to measure fatty acid
oxidation (e) as well as fatty acid (f), triglyceride (g), and cholesterol (h) syn-
theses. **, p 0.01; ***, p 0.001 as determined by Student’s t test. Standard
deviations are presented as error bars.
MiR-30cMimic and Hyperlipidemia
AUGUST 26, 2016•VOLUME 291•NUMBER 35 JOURNAL OF BIOLOGICAL CHEMISTRY 18403
MiR-30cMimic and Hyperlipidemia
18404 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 35•AUGUST 26, 2016
plasma cholesterol and atherosclerosis were not accompanied
with increases in plasmaALT, AST, and CK, indicating that the
miR-30c mimic was not causing any obvious liver and muscle
injury. Thus, these studies suggest thatmiR-30cmimic could be
developed into a safe, long lasting, and effective therapeutic
agent for lowering plasma cholesterol.
MiR-30c mimic most likely reduces plasma cholesterol by
lowering the production of apoB-containing lipoproteins
through suppression of MTP activity as these reductions were
not seen in L-Mttp/ mice. In contrast, miR-30c reduced
hepatic fatty acid and triglyceride syntheses inL-Mttp/mice,
indicating that it affects these processes independently of MTP
(34). Thus, the miR-30c mimic acts via MTP-dependent and
-independentmechanisms to control plasma andhepatic lipids,
respectively.
MiR-30c mimic reduced lipoprotein production but did not
cause steatosis usually associatedwith reductions in lipoprotein
production. One possibility is that miR-30c modestly dimin-
ished MTP activity, making it insufficient to induce steatosis.
Another possibility is that reductions in de novo lipogenesis and
triglyceride synthesis mitigate steatosis associated with reduc-
tions in lipoprotein secretion. A clue for the balancing act
between lipid synthesis and lipoprotein secretion came from
studies in L-Mttp/mice. In thesemice, therewere significant
reductions in hepatosteatosis comparedwith controls, suggest-
ing that, in the absence of lipoprotein secretion, reductions in
FIGURE 8. Global changes in hepatic gene expression pursuant to miR-30c mimic accretion. a, Venn diagrams showing the number of down-regulated
(left) and up-regulated (center) genes shared between mimic versus PBS and mimic versus Scr, respectively. The numbers of up-regulated (Up) and down-
regulated (Down) genes shared betweenmimic versus PBS and Scr versus PBS are shown. Genes that reached an expression threshold of counts permillion1
in threeormore sampleswere analyzed for differential expression.Geneswere considereddifferentially expressed if they reacheda -fold change cutoff of1.5
and false discovery rate (FDR) 0.05. b, miR-30abcde predicted target sites (these miRs share the same seed sequence) are enriched only in the genes
significantly down-regulated bymiR-30cmimic. Genes that reached an expression threshold of counts permillion1 in three ormore sampleswere analyzed
for differential expression if they reached a -fold change cutoff of1.5 and FDR0.05. The y axis shows thelog10(FDR-adjusted p value) of themiR-30abcde
miRHub enrichment score. FDR 0.05 is indicated by the gray dashed line. “Common” represents differentially expressed genes common to bothmimic versus
PBS and mimic versus scrambled. c and d, gene ontology (GO) enrichment analysis of differentially expressed genes common to both mimic versus PBS and
mimic versus Scr was conducted using Enrichr. c, all gene ontology biological process terms that reached an FDR cutoff of 0.001. d, a network of gene ontology
biological process terms enriched in the down-regulated genes. Each node represents an enriched term, and each link indicates gene content overlap. Green
bars show the log10(FDR), and red bars show the combined score,which is computedbymultiplying the log10(p value) fromaFisher’s exact testwith the z-score
of the deviation from the expected rank.
FIGURE 9.MiR-30cmimic causes regression of diet-induced atherosclerosis. Female Apoe/mice (8 weeks old) were fed a Western diet for 4 weeks and
then injected weekly with PBS or 7.5 mg/kg/week miR-30c mimic (n  5 per group) for another 4 weeks. a, fasting plasma was collected 4 days after each
injection tomeasure cholesterol. b and c, 48 h after the last injection, tissues were collected tomeasuremiR-30c levels (b). Hepatic tissuewas used tomeasure
MTP activity (c). d, aortic archeswere exposed andphotographed. e and f, aortaswere collected, fixed, stainedwithOil RedO (e), andquantified (f). The data are
representative of three experiments. *, p 0.05; **, p 0.01 as determined by Student’s t test. Standard deviations are presented as error bars.
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de novo lipogenesis might lower hepatic lipids. Furthermore,
comprehensive transcriptome analysis revealed that miR-30c
mimic predominantly suppresses lipogenic programs in the
liver. Consistent with this finding, physiological studies suggest
that miR-30c mimic likely avoids hepatosteatosis in mice by
reducing hepatic de novo lipogenesis and triglyceride synthesis.
Thus, miR-30c might maintain hepatic lipids by inhibiting at
least two pathways, lipid synthesis and lipoprotein secretion.
We did not see significant reductions in fasting plasma trig-
lyceride. This was unexpected as miR-30c mimic reduced pro-
duction of triglyceride-rich lipoproteins. No effect on plasma
triglyceride is most likely secondary to complete hydrolysis of
triglycerides by lipoprotein lipase in control mice. This can be
tested in the future by studying the effect of miR-30c in lipo-
protein lipase-deficient animals.
We used two controls, PBS and Scr, to evaluate the effects of
miR-30c mimic. Remarkably, very few differences were found
in the expression of genes and in the metabolic responses in
PBS and Scr groups. In contrast, the mimic group showed sig-
nificant differences compared with both controls. Thus, the
response seen with miR-30c mimic is specific to its biological
effect and is not related to RNA moiety or the vehicle used for
its delivery.
RNA-seq analysis showed that miR-30c mimic down-regu-
lated a small set (4%) of genes expressed in the liver. These
genes exhibited significant enrichment formiR-30c target sites.
Surprisingly, it increased the expression of twice asmany genes.
There was no significant enrichment of miR-30c target
sequence in the up-regulated genes, indicating that increases
are not due to direct effects. Mechanisms involved in the up-
regulation of genes need further investigation andmay uncover
novel regulatory mechanisms.
RNA-seq studies also revealed that miR-30c up-regulated
SREBP-2 and PCSK9. Therefore, we had anticipated increased
cholesterol synthesis and decreased lipoprotein clearance.
However, biochemical and physiological studies showed that
cholesterol synthesis was reduced and that LDL clearance was
normal. It is unclear why there is no correlation between
changes in mRNA levels of SREPB-2 and PCSK9 and expected
physiologic output.
These studies clearly show that miR-30c mimic can lower
plasma cholesterol and atherosclerosis. Although efficacious,
this mimic therapy can be improved further. First, a better
delivery method might avoid intravenous injections. Second,
use of other lipid formulations or nanoparticles may reduce the
amounts of mimic needed to lower plasma cholesterol. Third,
the mimic can be modified further to increase resistance to
ribonucleases. Fourth, modifications can be introduced to
increase its affinity for argonaute proteins to improve target
recognition. These and other improvements may increase the
efficacy ofmiR-30c-based drugs so that smaller amounts can be
administered with lesser frequency for long lasting plasma cho-
lesterol reductions.
In short, we show that miR-30c mimics can be used to lower
plasma cholesterol and atherosclerosis without causing steato-
sis and affecting plasma transaminases and creatine kinase
activity. Mechanistic studies identify two pathways (Fig. 10)
that are regulated by miR-30c that explain its beneficial thera-
peutic potential. First, it reduces MTP expression to lower
hepatic lipoprotein production. Second, it suppresses hepatic
lipid synthesis, and this might help avoid steatosis usually asso-
ciated with reduction in lipoprotein production. These proof-
of-concept and molecular studies provide strong impetus for
more preclinical studies in other animal models such as non-
human primates and subsequent human clinical trials.
Experimental Procedures
Materials—[14C]oleic acid, [3H]triolein, [3H]acetate, [3H]
glycerol, and 35S Pro-Mix were purchased from PerkinElmer
Life Sciences. Chemicals and solvents were from Fisher
Scientific.
Animals and Diet—Wild type and Apoe/ mice on a
C57BL/6J background were bred at SUNY Downstate Medical
Center. Mice were fed aWestern diet containing 17, 48.5, 21.2,
and 0.2% (by weight) protein, carbohydrates, fat, and choles-
terol, respectively (TD 88137, Harlan Teklad). All animal
experiments were approved by the Institutional Animal Use
and Care Committee of SUNY Downstate Medical Center.
MiR-30c Mimic Delivery to Mice—We custom synthesized
1 g of highly purifiedmirVanaTMmiRNAmimic (miR-30c) and
a non-targeting Scrmimic (Life Technologies). For their in vivo
delivery, Scr or miR-30c mimic was mixed with Invivo-
fectamine 2.0 (Life Technologies), incubated for 30 min at
50 °C, and dialyzed at room temperature for 90 min in 1 liter of
diethyl pyrocarbonate-treated PBS, pH 7.4, with gentle agita-
tion. This step is crucial to enhance encapsulation and remove
destabilizing solvents. Dialyzed complexes were collected, and
volumes were adjusted with PBS to obtain desired concentra-
tions. Mice fed a Western diet were injected weekly with the
indicated doses by retro-orbital injections. 48 h after the last
injection, mice were euthanatized, and tissues were harvested
and stored at80 °C for analysis.
Plasma and Tissue Lipid Measurements—Mice were fasted
overnight (15 h) before blood was collected in EDTA-rinsed
tubes from retro-orbital venous plexus. Blood was centrifuged
at 8,000 rpm for 5 min, and plasma was collected to enzymati-
FIGURE 10. Regulation of atherosclerosis and hepatic steatosis by miR-
30c. Our data show that miR-30c regulates expression of MTP and several
genes involved in fatty acid synthesis to reduce lipoprotein production and
lipid synthesis. Reduced plasma cholesterol may reduce atherosclerosis.
Reduced hepatic lipid synthesis may avoid steatosis usually associated with
diminished lipoprotein secretion.
MiR-30cMimic and Hyperlipidemia
18406 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 35•AUGUST 26, 2016
cally measure cholesterol and triglyceride concentrations using
kits (Thermo Scientific). HDL lipids were measured after pre-
cipitating plasma apoB-containing lipoproteins by the addition
of equal volumes of 0.4 M MgCl2 and 9.7 mM phosphotungstic
acid, pH 7.4. Lipids in apoB-containing lipoproteins were
deduced by subtracting the concentrations of HDL lipids from
total lipids. For hepatic lipid measurements, liver pieces (50
mg) were homogenized in buffer K (1mMTris-Cl, 1mM EGTA,
and 1 mM MgCl2, pH 7.6), and a portion was subjected to lipid
extraction.
Plasma Enzymes—Plasma ALT, AST (Biotron Diagnostics),
and CK (Fisher Scientific) were measured using kits according
to the manufacturers’ protocols.
Hepatic Triglyceride and ApoB Secretion—C57BL/6J mice
were fasted for 18 h, injected intraperitoneally with poloxamer
407 (90 mg ml1; 500 l) and 35S Pro-Mix (0.3 Ci per mouse)
intravenously. Blood was removed at the indicated time points.
For apoB secretion, plasma (100 l) was incubated with 1 g of
polyclonal antibody to apoB (Texas Academy Biosciences,
Product ID20A-G1) inNETbuffer (50mMTris, pH7.4, 150mM
NaCl, 5 mM EDTA, 0.5% Triton X-100, and 0.1% SDS) for 18 h.
Protein A/G-agarose beads (Santa Cruz Biotechnology) were
added to pull down apoB. Immunoprecipitated proteins were
separated by 5%SDS-PAGE (apoB) or 12%SDS-PAGE (apoA-I)
and exposed to PhosphorImager screens. Bandswere visualized
with a Storm 860 device (Amersham Biosciences) and quanti-
fied by ImageJ.
In Vivo Absorption of Lipids—C57BL/6J mice were injected
intraperitoneally with poloxamer 407 (90 mgml1; 500l). After
1 h, mice were fed a mixture of 2 Ci of [14C]cholesterol, 1 Ci
[3H]triolein, and 2 g/liter cholesterol (Sigma) in 50 l of olive oil.
Blood was collected retro-orbitally at the indicated time points,
and plasma was used for liquid scintillation counting.
ApoB Secretion fromCells—Huh-7 cells (250,000 cells/well in
a 6-well plate) were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin, and 1% L-glutamine in T75 flasks at
37 °C and 5% CO2 and transfected with either Scr or miR-30c
mimic using RNAiMAX (Invitrogen) according to the manufac-
turer’s instructions. Thenext day, 1ml of freshDMEMcontain-
ing 10% FBS was added, cells were collected after 10 h, protease
inhibitor mixture (Roche Applied Science) was added, cells
were centrifuged, and the supernatant was used to measure
apoB by ELISA (37).
MTP Activity Determination—Huh-7 cells or tissues (50
mg) were supplemented with a protease inhibitor mixture at 1
mg/ml. Then samples were homogenized in 1 ml of buffer K
and centrifuged (13,000 rpm, 30 min, 4 °C), and supernatants
were used for protein quantification and MTP assay using a
fluorescently labeled triglyceride transfer kit (Chylos, Inc.) (38).
mRNAQuantifications by Quantitative RT-PCR—Blood was
collected in EDTA-rinsed capillaries (Fisherbrand). Plasma
(200 l) was mixed with an equal volume of RNAgents Dena-
turing Solution (Promega) and incubated for 5 min at room
temperature. Next, 25 fmol of synthetic microRNA-39* from
Caenorhabditis elegans (cel-miR-39*, Life Technologies,
4464066) were added as a spiked-in control. Then 1 ml of TRI-
zol was added to the mixture, mixed vigorously for 10 s, and
incubated for 10min at room temperature. After adding 200l
of chloroform, the mixture was mixed on a vortex for 30 s and
allowed to stand for 5 min at room temperature. Following
centrifugation (12,000 rpm, 15 min, 4 °C), the aqueous phase
was transferred to a new tube, and glycogen (ThermoScientific)
was added at 1 g/l per sample. Subsequently, samples were
mixed with isopropanol and incubated at 80 °C for 2 h. Gly-
cogen enhances RNA recovery during alcohol precipitation.
Samples were centrifuged (10,000 rpm, 15 min, 4 °C), superna-
tants were discarded, and pellets were rinsed with cold 70%
ethanol, air-dried for 10 min, and dissolved in diethyl pyrocar-
bonate-treated water.
For gene expression, first strand cDNAwas synthesized with
the Omniscript RT kit (Qiagen) and used for quantitative RT-
PCR (qPCR Core kit for SYBR Green I, Eurogentec), and the Ct
values for each mRNA were normalized to 18S. For miR quan-
tification, cDNAwas synthesized with the TaqManMicroRNA
Reverse Transcription kit (Applied Biosystems, 4366597) and
used for quantitative RT-PCR. MiR analysis in cells and tissues
was performed using the 		Ct method with normalization to
small nucleolar RNA 202 or U6 and is presented as arbitrary
units. For miR-30c analysis in plasma, cel-miR-39* levels were
measured using their specific TaqMan microRNA assays (Life
Technologies, 464312) and used for the normalization of miR-
30c levels. Primers used for mRNA quantification were
designed using PrimerExpress 3.0 (Applied Biosystems) and are
listed in Table 1. Primers specific for miR-30c, small nucleolar
RNA 202, and U6 were purchased from Life Technologies.
Western Blotting Analyses—Liver tissues (50 mg) were
homogenized in buffer K (1 ml) containing protease inhibitor
mixture. Proteins (20 g) were resolved by SDS-PAGE (8%).
Amonoclonalmouse antibody tomouseMTP (BDBiosciences,
612022) and a rabbit antibody to mouse GAPDH (Santa Cruz
Biotechnology, sc-20356) were diluted 1:1000 and used as the
primary antibodies.Mouse Alexa Fluor 633 (Life Technologies,
A21052 and A21082, respectively) were used, and blots were
visualized using a Storm 860 device.
Fatty Acid Oxidation, de Novo Lipogenesis, and Triglyceride
Synthesis—For fatty acid oxidation, fresh liver slices were incu-
bated with [14C]oleic acid (0.3 Ci) for 2 h, and radiolabeled
CO2 was trapped with a filter paper soaked with phenylethyl-
amine. For de novo lipogenesis, fresh liver slices were incubated
with [3H]acetate (0.2 Ci), and lipids were extracted after
saponification (36). Triglyceride synthesis was studied by incu-
bating liver slices with [3H]glycerol (0.5 Ci), extracting lipids,
TABLE 1
Quantitative RT-PCR primers andmiR sequences
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and separating them on a silica 60 thin layer chromatography
plate using a solvent mixture of diethyl ether, benzene, ethanol,
and acetic acid at a ratio of 50:40:2:0.2. Counts were measured
in a scintillation counter (Beckman LS 6000 TA).
Aortic Plaque Analyses—The aortic arches were dissected
and exposed for photography. Lipids in fatty streaks were visu-
alized on the aorta with Oil Red O staining and quantified with
ImageJ (39, 40).
RNA Sequencing—RNA was isolated using a Norgen Animal
Tissue Purification kit (Norgen). Briefly, 15 mg of flash frozen
liver tissue was homogenized in lysis buffer using a 1.4-mm
ceramic lysing matrix (MP Biomedicals). RNA was purified
according to the manufacturer’s instructions, including the
optional on-column DNase I treatment. RNA was quantified
using Nanodrop 2000, and RNA quality was assessed using an
Agilent RNA 6000 Nano kit and Agilent 2100 Bioanalyzer.
TruSeq stranded mRNA libraries were prepared and paired-
end sequenced on a HiSeq 2500 sequencer with three to four
samples per lane at the University of North Carolina High
Throughput Sequencing Facility. Samples were demultiplexed
using CASAVA/bcl2fastq (v1.8.4). Data qualities were assessed
using Fastqc (v0.11.3) and aligned to the UCSC mm10 refer-
ence genome andBOWTIE index usingMapsplice (v2.1.4). The
“–fusion” parameter was used to search for both canonical and
semicanonical splice junctions. Alignments were sorted using
samtools (v0.1.19) and bedtools (v2.17.0). Multicov was used to
generate isoform count tables for differential gene expression
analysis using the UCSC mm10 known gene reference table,
which was accessed on June 9, 2015 and converted to bed for-
mat. Isoform counts were read into R version 3.1.2 (October 31,
2014). By taking the maximum count of all isoforms for a given
gene, we generated a table of gene counts. Genes were filtered for
low expression using the criterion counts per million1 in three
or more samples, and edgeR/3.8.6 was then used to normalize
remaining counts and conduct differential gene expression analy-
sis. RNA-seq data have been submitted to the Gene Expression
Omnibus (GEO) under accession number GSE70352.
Statistics—Data are presented as the mean S.D. (p 0.05).
The statistical significance was determined by Student’s t test
or one-way or two-way analysis of variance (GraphPad Prism),
and significant differences p 0.05, p 0.01, and p 0.001 are
symbolized as *, #, or @, respectively.
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measurement, lipid measurement, lipoprotein precipitation, and
atherosclerosis techniques and participated in radiolabeling and
FPLC experiments. B. C. E. P. performed RNA-seq studies, analyzed
data, and plotted the corresponding figures. P. S. supervised the
RNA-seq studies and revised the manuscript. M. M. H. conceived
the ideas, designed and discussed experiments, supervised the pro-
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